New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response

Analyses Examined Responses in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Relapsed or Refractory Mantle Cell Lymphoma -- Kite, a Gilead Company (NASDAQ:GILD), today announced findi